Zacks Research Has Bearish Estimate for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Investment analysts at Zacks Research dropped their Q1 2026 earnings estimates for Sarepta Therapeutics in a report released on Tuesday, April 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $2.44 per share for the quarter, down from their prior forecast of $2.56. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q2 2026 earnings at $2.76 EPS, Q3 2026 earnings at $2.82 EPS, Q4 2026 earnings at $2.62 EPS, FY2026 earnings at $10.64 EPS and FY2027 earnings at $12.25 EPS.

Several other equities analysts have also commented on the company. Morgan Stanley dropped their target price on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Wells Fargo & Company began coverage on shares of Sarepta Therapeutics in a research note on Friday. They set an "overweight" rating and a $115.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Royal Bank of Canada cut Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their target price for the company from $161.00 to $87.00 in a report on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $161.83.

Remove Ads

Sarepta Therapeutics Trading Down 2.3 %

SRPT traded down $1.27 during trading on Thursday, hitting $53.36. The company's stock had a trading volume of 975,692 shares, compared to its average volume of 1,391,042. Sarepta Therapeutics has a twelve month low of $48.01 and a twelve month high of $173.25. The stock has a market cap of $5.18 billion, a PE ratio of 42.69 and a beta of 0.93. The firm's 50 day moving average price is $86.82 and its 200-day moving average price is $109.61. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its position in shares of Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after purchasing an additional 12,000 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $3,829,000. Geode Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after acquiring an additional 44,306 shares during the period. Nordea Investment Management AB lifted its position in Sarepta Therapeutics by 19.1% in the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock valued at $8,228,000 after purchasing an additional 10,815 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after purchasing an additional 84,926 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.